1547 results about "Esterase" patented technology

A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided.

A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided.

The present invention relates to a method of removing a biofilm, which comprises at least the following steps, carried out simultaneously or consecutively: a) a solution comprising an enzyme mixture containing at least one enzyme chosen from the group of proteases, at least one enzyme chosen from the group of esterases and an amylase is prepared; b) a solution comprising a detergent with an alkaline pH is prepared; and c) said solutions are applied, by washing or by circulation, to the surface to be treated. It also relates to a kit intended for removing a biofilm, which comprises the solutions defined above and the compositions comprising the said solutions.

Enhanced removal and / or control of adhesives or sticky materials, “stickies”, from recovered paper stock or virgin pulp fibers is achieved using a combination of enzyme treatment with adsorbents and / or absorbents. Pulp stock to be treated is typically obtained from old magazines, newspapers, household waste, but may include corrugated boxes and office waste. Virgin pulps may include mechanical, chemical, or semi-chemical pulps. Enzymes typically include hydrolases such as cellulases, hemicellulases, pectinases, amylases, and lipases such as esterases, lyases such as pectate lyases, and oxidoreductases. Adsorbents include activated bentonite, microparticles, talc, clay and modified silica. Absorbents typically include water soluble polymers, dispersants, coagulatants and agglomerants.

Disclosed herein are multi-component formulations for enzymatically producing aqueous solutions of peroxycarboxylic acids suitable for use in, e.g., disinfectant and / or bleaching applications. The multi-component peroxycarboxylic acid formulations comprise at least one carbohydrate esterase family 7 enzyme having perhydrolytic activity.

Disclosed herein are multi-component peroxycarboxylic acid generation systems for enzymatically producing aqueous formulations of peroxycarboxylic acids suitable for use in, e.g., disinfectant and / or bleaching applications. The multi-component peroxycarboxylic acid generation systems comprise at least one carbohydrate esterase family 7 enzyme having perhydrolytic activity.

The present invention in one aspect relates to a coating composition comprising at least one enzyme capable of acting on a compound, wherein said action results in the formation of an antifouling species comprising an antifouling activity, and wherein said compound does not form part of said coating composition. The coating composition preferably comprises at least one oxidase capable of acting on a compound, such as a substrate for said oxidase, wherein said action results in the formation of an antifouling species including an antimicrobial species comprising an antimicrobial activity. More preferred, the oxidase comprises an activity which results in the formation of a peroxide. The oxidase can be present in said coating composition in combination with one or more additional enzymes including, but not limited to, an esterase, including a lipase, an amidase, including a protease, and a polysaccharide degrading enzyme, wherein said one or more additional enzyme(s), alone or in any combination, can be included in the presence or absence of one or more substrates for one or more of said enzymes.

RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+ / K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.

The present invention relates to a method of treating or preventing estrogen-suppressed tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula (I) in which formula R1, R2, R3, R4, independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and / or precursors. The estrogenic component according to the invention is particularly useful in the treatment or prevention of colorectal and prostate cancer and, unlike commonly used estrogens, does not simultaneously enhance the risk of estrogen-stimulated cancers such as breast cancer.

The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.

Disclosed herein are enzyme powders comprising a spray-dried formulation of at least one CE-7 esterase, at least one oligosaccharide excipient, and optionally at least one surfactant. Also disclosed herein is a process for producing peroxycarboxylic acids from carboxylic acid esters using the aforementioned enzyme powders. Further, disinfectant and laundry care formulations comprising the peracids produced by the processes described herein are provided.

Disclosed herein is a method for stabilization of the perhydrolase activity of the CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the mixture of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant and laundry care formulations comprising the peracids produced by the processes described herein are provided.

Carbamoyl esters inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. In one embodiment, the carbamoyl ester has the following structure: wherein A is selected from the group consisting of an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl and a substituted heteroaryl. The carbamoyl esters are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the carbamoyl esters can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.

Disclosed herein are compositions and methods to treat an oral cavity surface with a peracid-based benefit agent. The peracid benefit agent can be use for oral surface bleaching, whitening, disinfecting, destaining, deodorizing, decreasing or removing biofilm, and combinations thereof. The peracid is enzymatically generated from a carboxylic acid ester substrate using a CE-7 carbohydrate esterase having perhydrolytic activity (perhydrolase) in the presence of a source of peroxygen. A fusion protein comprising the perhydrolase coupled to a peptidic component having affinity for an oral cavity surface, either directly or through an optional linker, may be used to target the perhydrolytic activity to the oral cavity surface.

The invention discloses a 4'-carbamate derivative of scutellarin shown in formula (I), a preparation method of the compound and application of the compound in preparing medicines for preventing and / or treating various symptoms and diseases caused by acetyl cholinesterase and / or mediated by free radicals, such as vascular dementia and Alzheimer's disease. In the formula, each of R1, R2 and R3 independently represents H, C1-C12 alkyl or R6CO, wherein R6 represents C1-C12 alkyl, but R1, R2 and R3 are not H at the same time; each of R4 and R5 independently represents H, C1-C12 alkyl, C1-C6 fatty alcohol, or an ester formed by the C1-C6 fatty alcohol and C1-C6 carboxylic acid, the C1-C6 carboxylic acid, or an ester formed by the C1-C6 carboxylic acid and the C1-C6 fatty alcohol; or R4NR5 represents a morpholine ring, a piperidine ring, a 4-benzyl piperidine ring, a piperazine ring, the piperazine ring with the 4-position substituted by C1-C12 alkyl, or a tetrahydropyrrole ring.

The invention discloses preparation and application of total alkaloids extract and effective components in peganum plant seeds. The peganum plant (comprising harmel, multisectum peganum and peganum nigellastrum) seeds are heated, refluxed and extracted by ethanol, dissolved along with heat, acidulated by added 2 to 10 percent hydrochloric acid, and basified by ammonia water to separate out sediment; and the sediment is dried to obtain the total alkaloids extract mainly containing dehydrogenized peganine and peganine according to a proportion of between 0.18 to 1 and 4.30 to 1, wherein the content of the total alkaloids is more than 50 percent. The total alkaloids extract is separated by chromatography to obtain ten effective monomer components such as the dehydrogenized peganine, the peganine, and the like. Through thin layer chromatography and biological self-developing analysis, the total alkaloids extract and the effective monomer components thereof have the effect of resisting activity of acetylcholine esterase, and can be used for preparing medicament for resisting the activity of the acetylcholine esterase and medicament for treating neurodegenerative diseases.

The present invention provides a novel compound having an excellent acetylcholinesterase inhibitory effect. That is, it provides a 4-substituted piperidine compound fluoride represented by the following formula, a pharmaceutically acceptable salt thereof or hydrates thereof (provided that 1-benzyl-4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine, a pharmaceutically acceptable salt thereof and hydrates thereof are excluded).wherein R<1 >and R<2 >represent substituents.

A sensor and method for detecting biological and chemical agents comprising metal interdigitized electrodes coated with hybrid polymer-based conducting film and an instrument for applying electrical voltage to the electrodes and registering the change in electrical current. The hybrid film also comprises indicator biomolecules encapsulated within the film or attached to it. The bioindicator molecules preferably comprise enzyme acetylcholinesterase. When these indicator biomolecules come in a contact with a pathogen, chemical and / or morphological changes occur in the film and electrical current flowing through the electrodes is modulated. The pathogen comprise inhibitors of enzymes, preferably organophosphates, thiophosphates or phosphonates. The change in current indicates the presence of a biological and chemical agent and is registered.

Agents for improving potentcy of the urinary bladder which comprises an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholine esterase and an action to improve the excretory potency of urinary bladder. As an example, crystals of of 8-[3-[1-[(3-fluorophenyl)-methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof and pharmaceutical compositions containing them are disclosed.

The invention discloses a method that uses esterase obtained by 100 percent deinking and desizing of wasted newspaper controls sticky which mainly aims at producing the low fixed amount newspaper by using the 100 percent deinking and desizing of the wasted newspaper, adopts Optimyze 525 esterase control sticky and produces the newspaper with 45g / mm<2> fixed amount. The invention has the advantages of reducing the dosage of the sticky in the paper pulp, leading the sticky removing rate to be about 20 percent to 40 percent, reinforcing the operating performance of a paper machine, and helping to improve the speed and the output of the paper machine; by adopting deinking and desizing of 100 percent wasted newspaper to make 45g / m<2> lowing amount offset newsprint, the obtained products have good quality, chemical pulp and groundwood pulp which are high in pollution and high consumption are eliminated, the manufactory cost of the pulp material and the processing cost of the water are reduced, and the discharged waste water and the pollutants are reduced.

The present invention relates to methods and compositions for reactivating Acetylcholinesterase in living organisms using contents from the Morinda citrifolia L. plant. More particularly, the present invention relates to methods and compositions involving the reactivation of Acetylcholinesterase using fruit juice obtained from the Morinda citrifolia L. plant.

A process is provided for producing target concentrations of peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity under conditions where control of reaction pH by selection of buffer concentration and concentration of perhydrolase and reactants produces a targeted concentration of peroxycarboxylic acids. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided, as are corresponding methods of use.

The present invention provides plant fiber expansion (FE) genes that encode FE polypeptides, such as phosphoenol pyruvate carboxylase (PEPcase), expansin, endoglucanase, xyloglucan endoglycosyltransferase (XET), and pectin methyl esterase (PME). The invention further provides fiber-specific promoters. Still further, the invention provides molecular strategies for modulating fiber quality and yield in fiber producing plants by modulating expression of FE genes or mutant forms of FE genes.

In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and / or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.

The invention relates to tetrahydrothieno-[2,3-c]pyridine deuterated derivatives and a preparation method and medicament applications thereof, belonging to the field of medicinal chemistry. The derivatives contain salt of a compound in the formula I, and enantiomer and racemate of the compound in the formula I. The in-vitro whole-blood hydrolysis experiment results show that the stability of the compound in the formula I on esterase is good, and the hydrolysis rate of methyl carboxylate is obviously slower than that of non-deuterated methyl ester. The compound in the formula I can be effectively converted into pharmacological active metabolite in a human body to achieve the effect of inhibiting the platelet aggregation, and the concentration of the active metabolite is obviously higher than that of a non-deuterated compound of clopidogrel or a corresponding structure. The pharmacodynamic experiment results show that the compound in the formula I has the effect of obviously inhibiting the platelet aggregation, and the effect of inhibiting the platelet aggregation is obviously better than that of the non-deuterated compound of clopidogrel and the corresponding structure. Therefore, the compound in the formula I can be used for preparing medicaments for preventing or treating related thrombus and embolism diseases.

The invention relates to a test paper tape which can be used in the gynecological multiprogramming dry-chemistry joint detection. The test paper tape provided by the utility model comprises a dry-chemistry multiprogramming detection test paper tape which consists of a plastic substrate tape and various solidified regent blocks, and sample diluent. The dry regent blocks include combinations formed by increasing or decreasing at least three or more regent blocks of a Ph test regent block, a lactic acid regent block, a hydrogen peroxide concentration regent block, a leukocyte esterase concentration regent block, a neuraminidase activity regent block, an amine test regent block, a proline aminopeptidase substrate reagent block, an oxidase substrate reagent block, a N-acetylamine hexosidase substrate reagent block, a trichomonas specific protease substrate hydrolysis reagent block. the gynecological multiprogramming dry-chemistry joint detection test paper test provided by the utility model can detect Ph, lactic acid, hydrogen peroxide, leukocyte esterase, neuraminidase, amine test, proline aminopeptidase, oxidase, N-acetylamine hexosidase and trichomonas specific protease which are contained in leucorrhea sample at the same time, and can accurately reflect the microorganism environment of a women reproductive tract, the cleanness of leucorrhea secretion and the conditions of Candida albicans, trichomonas, gonococcus and the pathogens of bacterial vaginosis, thereby making the gynecological trichomonas detection more comprehensive; besides, the test paper tape provided by the utility model can be used easily and conveniently, and results can be obtained quickly. If the test paper tape is used together with a gynecological dry-chemistry analyzer, the operation can become easier and the result can be obtained more quickly.

RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+ / K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.

A feed additive composition comprising a direct fed microbial (DFM), in combination with a xylanase (e.g. endo-1,4-β-d-xylanase) and a β-glucanase (and optionally a further fibre degrading enzyme), wherein the DFM is selected from the group consisting of an enzyme producing strain; a C5 sugar-fermenting strain; a short-chain fatty acid-producing strain; a fibrolytic, endogenous microflora-promoting strain; or combinations thereof. The DFM may be selected from the group consisting of: Bacillus subtilis AGTP BS3BP5, Bacillus subtilis AGTP BS442, B. subtilis AGTP BS521, B. subtilis AGTP BS918, Bacillus subtilis AGTP BS1013, B. subtilis AGTP BS1069, B. subtilis AGTP 944, B. pumilus AGTP BS 1068 or B. pumilus KX11-1, Enterococcus faecium ID7, Propionibacterium acidipropionici P169, Lactobacillus rhamnosus CNCM-1-3698, Lactobacillus farciminis CNCM-1-3699, a strain having all the characteristics thereof, any derivative or variant thereof, and combinations thereof and the further fibre degrading enzyme may be selected from the group consisting of a cellobiohydrolase (E.C. 3.2.1.176 and E.C. 3.2.1.91), a β-glucosidase (E.C. 3.2.1.21), a β-xylosidase (E.C. 3.2.1.37), a feruloyl esterase (E.C. 3.1.1.73), an α-arabinofuranosidase (E.C. 3.2.1.55), a pectinase (e.g. an endopolygalacturonase (E.C. 3.2.1.15), an exopolygalacturonase (E.C. 3.2.1.67) or a pectate lyase (E.C. 4.2.2.2)), or combinations thereof.

A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression. In one preferred embodiment, the disease is dementia with Lewy Bodies. New formulations for quaternary ammonium anti-cholinergic muscarinic receptor antagonists are also disclosed.